01/28/2026
**Exciting update on affordable weight-loss meds!** 💊🏋️♂️
The Trump administration (via CMS) has announced the **BALANCE model** — a new **voluntary payment program** designed to boost access to **GLP-1 drugs** (like Zepbound, Wegovy, etc.) for weight management, diabetes, and metabolic health in certain Medicare and Medicaid beneficiaries.
Key highlights:
- CMS will negotiate directly with drug manufacturers for **lower prices**, standardized coverage rules, and caps on out-of-pocket costs (e.g., as low as **$50/month** for eligible Medicare folks in related demos).
- It pairs the meds with **lifestyle support** (diet, exercise, nutrition counseling) to promote long-term health — not just the drug alone.
- **Voluntary** for drug makers, states (Medicaid), and Medicare Part D plans — manufacturers had until Jan 8 to apply.
- Rollout: Short-term Medicare demo starts **July 2026** as a bridge; full BALANCE model for Medicaid in **May 2026** and Medicare Part D in **Jan 2027**.
- Builds on earlier deals slashing prices (e.g., $245/month government pay for some injectables) and aims to make these game-changing drugs more affordable and accessible while controlling costs.
This could be a big win for folks struggling with obesity-related issues, especially since Medicare doesn't normally cover these just for weight loss. Mixed expert views on how many will participate and long-term budget impacts, but it's a step toward broader access!
What do you think — will this help more people get the support they need? 😊
Full details: https://achi.net/newsroom/trump-administration-announces-new-voluntary-payment-model-for-weight-loss-drugs/
The Trump administration has announced plans for a new voluntary payment model intended to increase access to GLP-1 drugs — a class of medications often used for weight loss and the treatment of diabetes and other chronic conditions — for certain Medicare and Medicaid beneficiaries.